David Hoey

Mr. Hoey has extensive experience relevant to our Company, with more than 25 years’ experience in technology financing and commercialization. Mr. Hoey is a US-based director and his primary expertise is in business development, strategic planning, market development, corporate partnering and financings for medical technologies, diagnostics and drug development. His skills and experience are invaluable to the ongoing commercialization and launch of the Company’s products, especially in the United States.

Mr. Hoey has served as a non-executive director since March 2016 and has served as a director of Universal Biosensors LLC since August 2021. He has served as a director of Universal Biosensors B.V. since September 2021. Mr. Hoey has been a member of the Audit and Compliance Committee between March 2016 and February 2022 and as a member of the Remuneration & Nomination Committee between June 2016 and September 2017. Mr. Hoey was reappointed as a member of the Remuneration & Nomination Committee between January 2019 and February 2022. Mr. Hoey has served as a member of the Products and Projects Committee since February 2022.

Mr. Hoey is currently Chief Executive Office and a director of Vaxxas, Inc., a company which has developed and is commercializing a novel vaccine delivery technology – The NanopatchTM. He also serves as an advisor to Healthcare Ventures LLC. During his career Mr. Hoey has worked in management and leadership roles in the preclinical development of small molecule and biologic therapeutics, molecular diagnostic assays and platforms, and analytical instrumentation. Mr. Hoey served as vice president of business development at PathoGenetix, Inc., a company pioneering single molecular detection technologies for biodefence, clinical, and industrial applications.